Evidence map›Paper›PMID 24594990›Full record

ArticlePloS one2014

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Luis M Beltrán, Rocío Muñoz Hernández, Rebeca S de Pablo Bernal, José S García Morillo, Jesús Egido, Manuel Leal Noval, Sara Ferrando-Martinez, Luis M Blanco-Colio, Miguel Genebat, José R Villar and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic Review.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2023
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Targeting of CD163International journal of molecular sciences · 2020
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Luis M BeltránInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones Científicas/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular, Sevilla, Spain; Unidad Metabólico-Vascular, Fundación de Investigación IdiPAZ-Hospital Universitario La Paz, Madrid, Spain.
Rocío Muñoz HernándezInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones Científicas/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular, Sevilla, Spain.
Rebeca S de Pablo BernalLaboratorio de Inmunovirología, Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones científicas/Universidad de Sevilla, Sevilla, Spain.
José S García MorilloInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones Científicas/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular, Sevilla, Spain.
Jesús EgidoLaboratorio de Patología Vascular, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders, Madrid, Spain.
Manuel Leal NovalLaboratorio de Inmunovirología, Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones científicas/Universidad de Sevilla, Sevilla, Spain.
Sara Ferrando-MartinezLaboratorio de Inmunovirología, Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones científicas/Universidad de Sevilla, Sevilla, Spain; Laboratorio Inmunobiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain.
Luis M Blanco-ColioLaboratorio de Patología Vascular, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain.
Miguel GenebatLaboratorio de Inmunovirología, Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones científicas/Universidad de Sevilla, Sevilla, Spain.
José R VillarInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones Científicas/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular, Sevilla, Spain.
Rafael Moreno-LunaInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Centro Superior de Investigaciones Científicas/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular, Sevilla, Spain; Department of Vascular Physiopathology, Hospital Nacional de Parapléjicos, Servicio de Salud de Castilla La Mancha, Toledo, Spain.
Juan Antonio MorenoLaboratorio de Patología Vascular, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain.
Universidad de Sevilla · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario Virgen del Rocío · ESInstituto de Biomedicina de Sevilla · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients infected with the human immunodeficiency virus (HIV) have an increased risk of cardiovascular disease due to increased inflammation and persistent immune activation. CD163 is a macrophage scavenger receptor that is involved in monocyte-macrophage activation in HIV-infected patients. CD163 interacts with TWEAK, a member of the TNF superfamily. Circulating levels of sTWEAK and sCD163 have been previously associated with cardiovascular disease, but no previous studies have fully analyzed their association with HIV.

objectiveThe aim of this study was to analyze circulating levels of sTWEAK and sCD163 as well as other known markers of inflammation (hsCRP, IL-6 and sTNFRII) and endothelial dysfunction (sVCAM-1 and ADMA) in 26 patients with HIV before and after 48 weeks of antiretroviral treatment (ART) and 23 healthy subjects.

resultsPatients with HIV had reduced sTWEAK levels and increased sCD163, sVCAM-1, ADMA, hsCRP, IL-6 and sTNFRII plasma concentrations, as well as increased sCD163/sTWEAK ratio, compared with healthy subjects. Antiretroviral treatment significantly reduced the concentrations of sCD163, sVCAM-1, hsCRP and sTNFRII, although they remained elevated when compared with healthy subjects. Antiretroviral treatment had no effect on the concentrations of ADMA and sTWEAK, biomarkers associated with endothelial function. The use of protease inhibitors as part of antiretroviral therapy and the presence of HCV-HIV co-infection and/or active HIV replication attenuated the ART-mediated decrease in sCD163 plasma concentrations.

conclusionHIV-infected patients showed a proatherogenic profile characterized by increased inflammatory, immune-activation and endothelial-dysfunction biomarkers that partially improved after ART. HCV-HIV co-infection and/or active HIV replication enhanced immune activation despite ART.

Indexed as

AdultAntigens, CDAntigens, Differentiation, MyelomonocyticAnti-Retroviral AgentsArginineCase-Control StudiesCD163 AntigenCoinfectionC-Reactive ProteinCytokine TWEAKFemaleHepacivirusHepatitis CHIVHIV InfectionsHumansAntigens, CDAntigens, Differentiation, MyelomonocyticAnti-Retroviral AgentsArginineCD163 AntigenC-Reactive ProteinCytokine TWEAKInterleukin-6N,N-dimethylarginineReceptors, Cell SurfaceTNFSF12 protein, humanTumor Necrosis FactorsVascular Cell Adhesion Molecule-1

Identifiers

PMID24594990
PMCPMC3942443
OpenAlexW2083035454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.